2023-12-04 10:00:34 ET
%Obesity and diabetes have become a problem for developed world countries. To address the global rise of these issues, this company is pursuing a dual-gene therapy strategy using proprietary bionanotechnological approaches. The rational design of tissue-targeted bioresponsive gene delivery systems (completed) will now be accompanied by gene- and protein-silencing in animal models of obesity and diabetes.
%PreveCeuticalMedical (CSE: PREV) (OTC: PRVCF) announced in a press release today that it has begun preparations to accelerate the completion of its preclinical dual gene therapy program using their developed and in vitro validated Smart-siRNA sequences, which when paired with their proprietary and patented bioresponsive lipid-nanoparticulate delivery systems effectively target the PTPN1 gene.
The firm has received direct interest in its diabetes and obesity dual gene therapy program from a world-leading pharmaceutical company established in the diabetes and obesity therapeutic space. Explicit interest in the gene target has been expressed while also requesting the completion of gene-protein silencing efficacy and safety evaluation studies in rodent disease models, employing the firm's lead Smart-siRNA bio-responsive carrier systems.
Canadian shares closed Friday trade at $0.025.
About AllPennyStocks.com Media Inc.:
AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals.